Tyler Tarr, Ph.D.

Graduated: December, 2015
Mentor: Dr. Stephen Meriney
Thesis: Utilizing presynaptic structure-function properties to inform the design of novel therapies for neuromuscular disease
Current Position: Postdoctoral fellow, University of Maryland
Prior Degree: BS University of Pittsburgh (2010)


Tarr, T.B., Wipf, P. and Meriney, S.D. Synaptic pathophysiology and treatment of Lambert-Eaton myas-thenic syndrome. Molecular Neurobiology, 2014, doi:10.1007/s12035-014-8887-2.

Tarr, T.B., Lacomis, D., Reddel, S.W., Liang, M., Valdomir, G., Frasso, M., Wipf, P. and Meriney, S.D. Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist. J. Physiology 592: 3687-96, 2014.

Tarr, T.B., Malick, W., Liang, M., Valdomir, G., Frasso, M., Lacomis, D., Reddel, S.W., Garcia-Ocano, A., Wipf, P., Meriney, S.D. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton Myasthenic Syndrome. J. Neuroscience 33: 10559-10567, 2013.

Tarr, T.B., Dittrich, M. and Meriney, S.D. Are Unreliable Release Mechanisms Conserved from NMJ to CNS? Trends Neurosci. 36: 14-22, 2013.

Liang, M., Tarr, T.B., Bravo-Altamirano, K., Valdomir, G., Rensch, G., Swanson, L., DeStefino, N.R., Mazzarisi, C.M., Olszewski, R.A., Wilson, G.M., Meriney, S.D. and Wipf, P. Synthesis and Biological Evaluation of a Selective N- and P/Q-Type Calcium Channel Agonist. ACS Med. Chem. Lett. 3: 985-990, 2012

Tarr, T.B., Valdomir, G., Liang, M., Wipf, P. and Meriney, S.D. New calcium channel agonists as potential therapeutics in LEMS and other neuromuscular diseases. Ann. N.Y. Acad. Sci. 1275: 85-91, 2012.